Journal article icon

Journal article

Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia

Abstract:

Rationale

N-Acetylcysteine (NAC) is currently under investigation as an adjunctive treatment for schizophrenia. The therapeutic potential of NAC may involve modulation of brain glutamate function, but its effects on brain glutamate levels in schizophrenia have not been evaluated.

Objectives

The aim of this study was to examine whether a single dose of NAC can alter brain glutamate levels. A secondary aim was to characterise its effects on regional brain perfusion.

Methods

In a double-blind placebo-controlled crossover study, 19 patients with a diagnosis of schizophrenia underwent two MRI scans, following oral administration of 2400 mg NAC or matching placebo. Proton magnetic resonance spectroscopy was used to investigate the effect of NAC on glutamate and Glx (glutamate plus glutamine) levels scaled to creatine (Cr) in the anterior cingulate cortex (ACC) and in the right caudate nucleus. Pulsed continuous arterial spin labelling was used to assess the effects of NAC on resting cerebral blood flow (rCBF) in the same regions.

Results

Relative to the placebo condition, the NAC condition was associated with lower levels of Glx/Cr, in the ACC (P < 0.05), but not in the caudate nucleus. There were no significant differences in CBF in the NAC compared to placebo condition.

Conclusions

These data provide preliminary evidence that NAC can modulate ACC glutamate in patients with schizophrenia. In contrast, physiological effects of NAC on the brain were not detectable as between session changes in rCBF. Future studies assessing the effects of a course of treatment with NAC on glutamate metabolites in schizophrenia are indicated.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1007/s00213-018-4997-2

Authors

More by this author
Role:
Author
ORCID:
0000-0001-8259-5439
More by this author
Role:
Author
ORCID:
0000-0003-3038-0625
More by this author
Role:
Author
ORCID:
0000-0001-7067-8616
More by this author
Role:
Author
ORCID:
0000-0002-9525-1560
More by this author
Role:
Author
ORCID:
0000-0002-5078-9025


Publisher:
Springer
Journal:
Psychopharmacology More from this journal
Volume:
235
Issue:
10
Pages:
3045-3054
Publication date:
2018-08-23
DOI:
EISSN:
1432-2072
ISSN:
0033-3158


Language:
English
Keywords:
Pubs id:
2359379
Local pid:
pubs:2359379
Source identifiers:
W2888654824
Deposit date:
2026-01-15
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP